Stockscreener 앱 받기
2.24
2.18%
-0.05
시간 외 거래:
2.25
0.010
+0.45%
Ocugen Inc 주식(OCGN)의 최신 뉴스
Ocugen, Inc. pushes innovation in modifier gene therapies to address blindness - Traders Union
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen (OCGN) Receives Buy Rating from Canaccord Genuity - GuruFocus
Ocugen a new buy at Canaccord on pipeline for retinal diseases (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports 2025 results and clinical progress across gene therapy pipeline - MSN
Ocugen Q4 2025 earnings preview - MSN
Canaccord Genuity initiates coverage of Ocugen (OCGN) with buy recommendation - MSN
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data - MSN
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen, Inc. (NASDAQ:OCGN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
OCGN Coverage Initiated by Canaccord Genuity with 'Buy' Rating a - GuruFocus
Canaccord Genuity Group Begins Coverage on Ocugen (NASDAQ:OCGN) - MarketBeat
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighWhat's Next? - MarketBeat
Ocugen Nears Critical Data Readout for Key Eye Disease Therapy - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Shares Down 4.6%Should You Sell? - MarketBeat
Ocugen Shares Surge Following Bullish Analyst Coverage - AD HOC NEWS
Ocugen (OCGN) Is Up 54.0% After Completing Phase 3 OCU400 Enrollment And Facing Going-Concern Warning - simplywall.st
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight - Yahoo Finance
Analyst Confidence Sparks Surge in Ocugen Shares - AD HOC NEWS
Ocugen Stock Jumps as Oppenheimer Initiates Outperform Rating - StocksToTrade
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Stock Surges Amid Positive Analyst Coverage and Clinical Progress - StocksToTrade
Ocugen Stock Surges Amid Oppenheimer’s Bullish Forecast - timothysykes.com
Ocugen, Inc. (NASDAQ: OCGN) Q4 2025 earnings call transcript - MSN
Ocugen Stock Soars Following Strategic Developments in Gene Therapy Trials - timothysykes.com
Ocugen (NASDAQ:OCGN) Shares Gap UpStill a Buy? - MarketBeat
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline - AOL.com
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - AOL.com
Ocugen, Inc. (OCGN) Stock Forecast 2027, 2031 & 7-Year Price Prediction | Meyka AI - Meyka
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story - Yahoo Finance
Ocugen (OCGN) Valuation Update As Phase 3 OCU400 Enrollment Completes And Going Concern Risks Persist - simplywall.st
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Ocugen (OCGN) Surges to 52-Week High on Oppenheimer's Outperform Rating - GuruFocus
Investors Buy Large Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen stock wins new Outperform at Oppenheimer (OCGN:NASDAQ) - Seeking Alpha
Ocugen (NASDAQ:OCGN) Hits New 12-Month HighWhat's Next? - MarketBeat
Ocugen (NASDAQ:OCGN) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
OCGN: Oppenheimer Initiates Coverage with Outperform Rating | OC - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for Ocugen - MarketBeat
Oppenheimer Initiates Ocugen at Outperform With $10 Price Target - marketscreener.com
Oppenheimer initiates Ocugen stock rating at Outperform on gene therapy potential - Investing.com
Ocugen price target raised to $22 from $15 at Lucid Capital - TipRanks
Oppenheimer initiates coverage of Ocugen (OCGN) with outperform recommendation - MSN
Ocugen's Clinical Ambition Meets Market Skepticism - AD HOC NEWS
Ocugen’s Gene Therapy Pipeline Dominates Earnings Call - TipRanks
Ocugen Faces Analyst Scrutiny Despite Pipeline Progress - AD HOC NEWS
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline - MyChesCo
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo! Finance Canada
FY2030 Earnings Forecast for Ocugen Issued By HC Wainwright - MarketBeat
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy - MyChesCo
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen: Downgrade "Hold" After OCU410 Data Release (NASDAQ:OCGN) - Seeking Alpha
312,319,623 Common Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Warrants of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Performance Stock Units of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Restricted Stock Units. of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Ocugen, Inc. honors women leaders advancing gene therapy innovation - Traders Union
1.20%
0.06%
자본화:
|
볼륨(24시간):